NO322962B1 - Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens - Google Patents
Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens Download PDFInfo
- Publication number
- NO322962B1 NO322962B1 NO19924528A NO924528A NO322962B1 NO 322962 B1 NO322962 B1 NO 322962B1 NO 19924528 A NO19924528 A NO 19924528A NO 924528 A NO924528 A NO 924528A NO 322962 B1 NO322962 B1 NO 322962B1
- Authority
- NO
- Norway
- Prior art keywords
- bssl
- protein
- amino acid
- treatment
- sequence
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims description 4
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 54
- 108090001060 Lipase Proteins 0.000 claims description 31
- 102000004882 Lipase Human genes 0.000 claims description 31
- 239000004367 Lipase Substances 0.000 claims description 31
- 235000019421 lipase Nutrition 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 description 50
- 102000004190 Enzymes Human genes 0.000 description 35
- 108090000790 Enzymes Proteins 0.000 description 35
- 229940088598 enzyme Drugs 0.000 description 35
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 108010051152 Carboxylesterase Proteins 0.000 description 23
- 102000013392 Carboxylesterase Human genes 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 22
- 108010058834 acylcarnitine hydrolase Proteins 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 229940040461 lipase Drugs 0.000 description 15
- 239000003833 bile salt Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000013598 vector Substances 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 10
- 210000005075 mammary gland Anatomy 0.000 description 10
- 229940093761 bile salts Drugs 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 7
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 6
- 206010025476 Malabsorption Diseases 0.000 description 6
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 4
- 102100036045 Colipase Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 101000876022 Homo sapiens Colipase Proteins 0.000 description 4
- 239000007993 MOPS buffer Substances 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000004293 human mammary gland Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- -1 vitamin esters Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000168726 Dictyostelium discoideum Species 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- 101000715643 Homo sapiens Bile salt-activated lipase Proteins 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100033504 Thyroglobulin Human genes 0.000 description 3
- 108010034949 Thyroglobulin Proteins 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 102000005311 colipase Human genes 0.000 description 3
- 108020002632 colipase Proteins 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 102000052905 human CEL Human genes 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 150000002759 monoacylglycerols Chemical class 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229960002175 thyroglobulin Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 2
- 108090000322 Cholinesterases Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- KRZWEBVPFGCYMY-UHFFFAOYSA-M methylmercury(1+);hydroxide Chemical compound [OH-].[Hg+]C KRZWEBVPFGCYMY-UHFFFAOYSA-M 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 102100036806 Carboxylesterase 5A Human genes 0.000 description 1
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 1
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 108700012227 Drosophila ase Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800133 Homo sapiens Thyroglobulin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 101710128782 Liver carboxylesterase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101000715641 Rattus norvegicus Bile salt-activated lipase Proteins 0.000 description 1
- 101100235661 Rattus norvegicus Lpl gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000251735 Torpedo marmorata Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 102000047688 human TG Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000003203 triacylglycerol group Chemical group 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9001985A SE9001985D0 (sv) | 1990-06-01 | 1990-06-01 | New chemical products |
| PCT/SE1991/000381 WO1991018923A1 (en) | 1990-06-01 | 1991-05-30 | Derivatives of human bile-salt stimulated lipase, and pharmaceutical compositions containing them |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO924528D0 NO924528D0 (no) | 1992-11-24 |
| NO924528L NO924528L (no) | 1992-11-24 |
| NO322962B1 true NO322962B1 (no) | 2006-12-18 |
Family
ID=20379662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19924528A NO322962B1 (no) | 1990-06-01 | 1992-11-24 | Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens |
Country Status (44)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP930935A2 (en) * | 1992-06-11 | 1994-12-31 | Astra Ab | New dna sequences |
| SE9300686D0 (sv) | 1993-03-01 | 1993-03-01 | Astra Ab | Novel polypeptides |
| IS4130A (is) * | 1993-03-01 | 1994-09-02 | Ab Astra | Ný fjölpeptíð |
| FR2754827B1 (fr) * | 1996-10-17 | 1998-12-24 | Biocem | Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations |
| JP2000026311A (ja) * | 1998-07-02 | 2000-01-25 | Amano Pharmaceut Co Ltd | 胃排出能亢進剤組成物 |
| US20090226904A1 (en) * | 2005-12-01 | 2009-09-10 | University Of Bergen | Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes |
| SI2561069T1 (sl) | 2010-04-23 | 2017-07-31 | Alexion Pharmaceuticals, Inc. | Encim za bolezen lizosomskega shranjevanja |
| KR20150038636A (ko) | 2010-09-09 | 2015-04-08 | 시나게바 바이오파르마, 코포레이션 | 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도 |
| RU2013123053A (ru) | 2010-10-21 | 2014-11-27 | Сведиш Орфан Биовитрум Аб (Пабл) | Способ увеличения скорости роста новорожденных детей |
| CA2812852A1 (en) | 2010-10-21 | 2012-04-26 | Swedish Orphan Biovitrum Ab (Publ) | Method to increase the absorption of unsaturated fatty acids by human infants |
| BR112019025973A2 (pt) * | 2017-06-19 | 2020-07-07 | Swedish Orphan Biovitrum Ab (Publ) | proteína de fusão com polipeptídeo de extensão de meia-vida |
| EP4022049A4 (en) | 2019-08-30 | 2023-11-01 | Codexis, Inc. | MODIFIED LIPASE VARIANTS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0131418A1 (en) * | 1983-07-01 | 1985-01-16 | Celltech Limited | Proteins, pharmaceutical compositons, genes, vectors, host organisms and processes for their production |
-
1990
- 1990-06-01 SE SE9001985A patent/SE9001985D0/xx unknown
-
1991
- 1991-05-17 ZA ZA913778A patent/ZA913778B/xx unknown
- 1991-05-18 TW TW080103838A patent/TW221712B/zh not_active IP Right Cessation
- 1991-05-20 DZ DZ910064A patent/DZ1503A1/fr active
- 1991-05-22 NZ NZ238223A patent/NZ238223A/xx not_active IP Right Cessation
- 1991-05-23 MY MYPI91000877A patent/MY111245A/en unknown
- 1991-05-27 IL IL9827391A patent/IL98273A/xx not_active IP Right Cessation
- 1991-05-29 YU YU95191A patent/YU49138B/sh unknown
- 1991-05-29 EG EG33391A patent/EG19937A/xx active
- 1991-05-29 MA MA22438A patent/MA22166A1/fr unknown
- 1991-05-30 WO PCT/SE1991/000381 patent/WO1991018923A1/en active IP Right Grant
- 1991-05-30 SG SG1996006887A patent/SG48078A1/en unknown
- 1991-05-30 CA CA002083396A patent/CA2083396C/en not_active Expired - Lifetime
- 1991-05-30 DE DE69125489T patent/DE69125489T2/de not_active Expired - Lifetime
- 1991-05-30 IE IE184491A patent/IE911844A1/en not_active IP Right Cessation
- 1991-05-30 ES ES91911030T patent/ES2099159T3/es not_active Expired - Lifetime
- 1991-05-30 RU RU92016526/13A patent/RU2140983C1/ru active
- 1991-05-30 UA UA93003780A patent/UA39165C2/uk unknown
- 1991-05-30 DK DK91911030.4T patent/DK0535048T3/da active
- 1991-05-30 RO RO92-01490A patent/RO114793B1/ro unknown
- 1991-05-30 PL PL91296937A patent/PL166534B1/pl unknown
- 1991-05-30 AU AU79645/91A patent/AU651979B2/en not_active Expired
- 1991-05-30 JP JP91510382A patent/JPH05507201A/ja active Pending
- 1991-05-30 HU HU9203774A patent/HU215258B/hu unknown
- 1991-05-30 AT AT91911030T patent/ATE151077T1/de not_active IP Right Cessation
- 1991-05-30 EP EP91911030A patent/EP0535048B1/en not_active Expired - Lifetime
- 1991-05-31 IS IS3710A patent/IS1751B/is unknown
- 1991-05-31 SK SK1644-91A patent/SK281089B6/sk not_active IP Right Cessation
- 1991-05-31 CZ CS19911644A patent/CZ287470B6/cs not_active IP Right Cessation
- 1991-05-31 PT PT97836A patent/PT97836B/pt not_active IP Right Cessation
- 1991-05-31 TN TNTNSN91041A patent/TNSN91041A1/fr unknown
- 1991-06-01 AP APAP/P/1991/000270A patent/AP207A/en active
- 1991-06-01 CN CN91104368A patent/CN1075113C/zh not_active Expired - Lifetime
- 1991-06-01 JO JO19911694A patent/JO1694B1/en active
- 1991-10-11 PH PH43285A patent/PH30761A/en unknown
-
1992
- 1992-10-01 HR HRP-951/91A patent/HRP920771B1/xx not_active IP Right Cessation
- 1992-11-24 NO NO19924528A patent/NO322962B1/no not_active IP Right Cessation
- 1992-11-26 BG BG97123A patent/BG61165B1/bg unknown
- 1992-11-30 KR KR1019920703049A patent/KR100212411B1/ko not_active IP Right Cessation
- 1992-11-30 FI FI925453A patent/FI114639B/fi active IP Right Grant
-
1993
- 1993-07-30 LV LVP-93-1005A patent/LV10292B/en unknown
- 1993-12-30 LT LTIP1736A patent/LT4020B/lt not_active IP Right Cessation
-
1997
- 1997-05-08 HK HK62497A patent/HK62497A/xx not_active IP Right Cessation
- 1997-05-30 GR GR970401262T patent/GR3023618T3/el unknown
-
2000
- 2000-11-20 CN CN00130975A patent/CN1326782A/zh active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morimoto et al. | Saposin A: second cerebrosidase activator protein. | |
| Lowe et al. | Cloning and characterization of human pancreatic lipase cDNA | |
| McLean et al. | Cloning and expression of human lecithin-cholesterol acyltransferase cDNA. | |
| JP3072853B2 (ja) | 治療用に、組換方法で生産されたリパーゼ | |
| NO322962B1 (no) | Anvendelse av et rekombinant protein for fremstilling av et preparat for behandling av tilstander relatert til eksokrin bukspyttkjertelinsuffisiens | |
| ES2459217T3 (es) | Producción enzimática de productos de lecitina hidrolizados | |
| JP2514167B2 (ja) | ポリペプチドとポリペプチド組成物 | |
| AU2006270921A1 (en) | Novel phospholipid processing agent | |
| HU221119B1 (en) | Variants of bile salt-stimulated lipase, dna molecules encoding them, and transgenic nonhuman mammals | |
| EP0131418A1 (en) | Proteins, pharmaceutical compositons, genes, vectors, host organisms and processes for their production | |
| O'Connor et al. | Ruminant pregastric lipases: experimental evidence of their potential as industrial catalysts in food technology | |
| KADNER et al. | Hormonally sensitive esterase activity in the mouse uterus results from uptake of plasma esterase | |
| JP5196469B2 (ja) | カルシウム結晶化阻害タンパク質 | |
| US20020006655A1 (en) | Purified proteolytic enzyme and method of purification | |
| Timmermans | Purification, mofecular cloning and expression of the cDNA of bovine pregastric esterase | |
| Bläckberg et al. | cDNA CLONING AND SEQUENCING OF HUMAN MILKBILE SALTSTIMULATED LIPASE | |
| JP2000333688A (ja) | 改質油脂組成物の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |